Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed supratentorial malignant primary glioma of one of the following subtypes:
• * Glioblastoma multiforme
• * Anaplastic astrocytoma
• * Anaplastic oligodendroglioma
• * Mixed malignant glioma
• Original histology of low-grade glioma allowed if subsequent histological confirmation of malignant glioma
• Measurable recurrent or residual primary disease by MRI
• * Lesions with clearly defined margins
• Evidence of tumor recurrence or progression by MRI or CT scan
• Confirmation of true progressive disease by PET or thallium scan, magnetic resonance spectroscopy, or surgical documentation after prior interstitial brachytherapy or stereotactic radiosurgery
• No more than 3 relapses after prior chemotherapy/cytotoxic therapy (including polifeprosan 20 with carmustine implant) for phase I and no more than 2 relapses for phase II
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 10 g/dL
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• SGOT no greater than 2 times upper limit of normal
• Renal:
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular:
• No uncontrolled hypertension, unstable angina, or symptomatic congestive heart failure
• No myocardial infarction within the past 6 months
• No serious uncontrolled cardiac arrhythmia
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No mental incapacitation
• HIV negative
• No AIDS-related disease
• No significant ongoing alcoholism or substance abuse
• No severe nonmalignant systemic disease
• No active infection
• No other severe disease that would preclude study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 1 week since prior interferon or thalidomide and recovered
• No concurrent anticancer immunotherapy
• No concurrent sargramostim (GM-CSF)
• No concurrent prophylactic filgrastim (G-CSF) during first course of study therapy
• Chemotherapy:
• See Disease Characteristics
• Recovered from prior chemotherapy
• At least 2 weeks since prior vincristine
• At least 3 weeks since prior procarbazine
• At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosourea)
• Prior radiosensitizers allowed
• No prior temozolomide or irinotecan
• No other concurrent anticancer chemotherapy
• Endocrine therapy:
• At least 1 week since prior tamoxifen and recovered
• No concurrent anticancer hormonal therapy
• Phase II:
• * Non-increasing dose of corticosteroids allowed
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy and recovered
• No concurrent anticancer radiotherapy
• Surgery:
• See Disease Characteristics
• At least 1-3 weeks since prior surgical resection and recovered
• Other:
• At least 1 week since prior noncytotoxic agents (e.g., isotretinoin) and recovered
• Concurrent enzyme-inducing anti-epileptic drugs with or without steroids allowed
• No concurrent valproic acid as a single agent
• No concurrent medication that would preclude study (e.g., nonsteroidal immunosuppressive agents)
• No other concurrent investigational drugs
• No concurrent participation in other clinical study